Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Apotex Inc. Acquires Topgen E.S.V. in Belgium from Zambon

20 Nov 2007 - Apotex Inc. announced the purchase from Zambon of the pharmaceutical company, Topgen, E.S.V. of Belgium. No acquisition price was disclosed. According to the company, Topgen, headquartered in Brussels, is the 7th largest generic pharmaceutical company in this country with approximately 30 generic registrations and has a nation-wide sales force that reaches over 4,000 doctors and 3,000 pharmacies.
 
"This acquisition represents an important milestone for Apotex International as it extends the organization's footprint in Europe and will be a launching pad for many E.U. products currently in the Apotex development pipeline," stated Andrew Kay, Apotex International President.
 
"The sale of Topgen furthers Zambon's strategy of focusing its Belgian operations on developing its portfolio of branded products, while simultaneously strengthening our relationship with Apotex, which is already a partner of Zambon and Chiesi in Italy through Doc Generici S.r.l.," explained Roberto Consonni, CEO of Zambon's Pharma Business.